Product Quantum (Rs. Cr) (SEBI) Quantum (Rs. Cr) (Other FSR) Long Term Rating Short Term Rating Regulated By
Bank Loan Ratings 0.00 15.40 ACUITE BBB | Stable | Reaffirmed - RBI
Bank Loan Ratings 0.00 15.00 - ACUITE A3+ | Reaffirmed RBI
Total Outstanding 0.00 30.40 - - -
Total Withdrawn 0.00 0.00 - - -
Note:- For activities or ratings of instruments falling under the purview of Financial Sector Regulators other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available.
 
Rating Rationale

­Acuité has reaffirmed the long-term rating of 'ACUITE BBB' (read as ACUITE triple Bon the Rs. 15.40 Cr. bank facilities and the short-term rating of 'ACUITE A3+' (read as ACUITE A three plus) on the Rs. 15.00 Cr. bank facilities of Pharmalab India Private Limited. The outlook is 'Stable'.

Rationale for rating reaffirmation

The rating derives comfort from PIPL's established presence in both domestic and export markets, supporting stable operating performance, with revenue growth of around 8% in FY26 (Estd) over FY25. The financial risk profile remains moderate, characterized by average net worth, low gearing, and stable debt protection metrics, along with adequate liquidity supported by sufficient net cash accruals against long- term debt obligations and moderate utilization of bank limits. However, the overall credit profile is constrained by intensive working capital requirements, primarily due to high inventory and receivables days. Profitability margins have also moderated owing to reduced exports, higher job work expenses, and further one-time impact of employee incentive payouts in FY26 in addition to regular increments. Going forward, the company’s ability to improve margins, sustain profitability, and efficiently manage its working capital will remain key monitorable factors.


About the Company

Pharmalab India Private Limited (PIPL) is a Mumbai-based company incorporated in 2006. The company is managed by a group of experienced directors, namely Mr. Umesh P. Shah, Mr. Karnik K. Parikh, Mr. Rashmikant P. Shah, Mr. Nitin P. Shah, Mr. Kunal U. Shah, Mr. Vishal U. Shah, and Mr. Jay K. Shah. The company caters to both domestic and international markets and exports its products to various countries including Bangladesh, USA, Middle East, and several African nations. The company is primarily engaged in the manufacturing of equipment such as Sterilisers, Multi-Column Distillation Plants, Pure Steam Generators, Filter Presses, and Hospital Sterilisers, which are widely used across industries including pharmaceuticals, chemicals, water treatment, beverages, distilleries, pesticides, food processing, and healthcare. In addition to manufacturing, the company undertakes installation services and annual maintenance contracts (AMC) for its clients. It also carries out trading activities linked to export orders, with trading contributing approximately 20–30% of its overall business operations.

 
Unsupported Rating
­­Not Applicable
 
Analytical Approach
­Acuité has considered the standalone financial and business risk profiles of PIPL to arrive at the rating.
 
Key Rating Drivers

Strengths

­Experienced management with an established track record of operations
PIPL has an operational track record of nearly two decades. The promoters and their families possess over four decades of experience in the machinery and equipment manufacturing business. The management is further supported by its well-qualified and experienced team of professionals managing day-to-day operations of PIPL. The extensive experience of the management and the established presence of the company have enabled PIPL to maintain a healthy relationship with a reputed clientele. Acuité believes that PIPL is likely to benefit from its experienced management and established track record of operations in the medium term.

Steady scale of operations
PIPL’s revenue moderated to Rs. 159.61 crore in FY25 from Rs. 166.26 crore in FY24, primarily due to a decline in export orders from Bangladesh amid geopolitical tensions. However, the company demonstrated resilience in its operations with revenue of Rs. 171.80 crore in FY26 (Estd), reflecting stable performance. The revenue mix has shifted significantly towards the domestic market, which contributed around 85% of total sales in FY26 (73% in FY25), while exports declined to about 15% (27% in FY25). Approximately 56% of total product sales are derived from key offerings such as Sterilisers, Multi-column Distillation Plants, and Pure Steam Generators, with realizations varying based on size, capacity, and customer specifications. Although decline in exports noted from FY25 onwards, the company has mitigated this risk by onboarding new domestic customers, thereby strengthening its domestic presence and reducing reliance on exports. Going forward, Acuité believes that PIPL’s operating performance is likely to improve, supported by its established presence in both domestic and international markets.

Moderate financial risk profile:
The financial risk profile of the company stood moderate marked by average net worth, low gearing and stable debt protection metrics. The total tangible net worth stood at Rs.66.21 crores in FY 25 as against Rs. 60.28 crores in FY 24, mainly driven by internal accruals. Total tangible net worth includes of Rs.7.49 crores of USL which has been subordinated to the debt. Gearing ratio remained below unity at 0.11 times in FY 25 (0.15 times in FY 24). Debt protection metrics stood healthy with Interest coverage ratio and Debt Service Coverage Ratio stood at 6.62 and 4.80 times in FY 25. Acuite believes financial risk profile is expected to be stable mainly on account of absence of major debt funded capex plan.


Weaknesses

Continuous moderation in margins:
The company’s operating margins declined to 7.82% in FY25 from 8.94% in FY24, primarily due to a reduction in high-margin export sales and an increase in job work expenses, which rose to Rs.9.52 crore in FY25 from Rs.8.41 crore in FY 24 owing to the outsourcing of fabrication work for customized equipment. Consequently, PAT margins also declined to 3.59% in FY25 from 5.32% in FY24, higher depreciation charges following the capitalization of Rs.8.29 crore largely towards renovation, repair, maintenance, and upgradation of existing facilities rather than capacity expansion. In FY26 (Estd), operating margins further softened to around 6.60%, mainly due to increased employee costs, including one-time incentive payouts of approximately Rs.1–1.5 crore (over and above regular increments), along with continued pressure from lower export sales and a slight moderation in overall realizations. Acuité believes that sustaining profitability margins will remain a key monitorable going forward.


Intensive working capital management:
The company’s working capital management remained intensive in FY25, as reflected by GCA days increasing to 252 days from 247 days in FY24, primarily driven by higher inventory levels. Inventory days rose sharply to 145 days in Fy 25 from 119 days in FY 24 due to a buildup in finished goods inventory at year end; the company’s normal inventory holding period remains at 4–5 months. Debtor days improved to 86 days in FY 25 from 108 days in FY 24, with the elevated receivables in FY24 attributable to a one-time LC-backed export order, while the company typically maintains a 70–90-day collection cycle supported by advance payments and milestone-based billing. Creditor days increased to 126 days in FY 25 from 103 days in FY 24 due to higher year-end purchases. Although the working capital cycle remains intensive, liquidity support from customer advances has kept bank limit utilization moderate.

 

Rating Sensitivities

Potential triggers (individual or collective) for an upward rating action:
  • ­Scale of operation increases to Rs.200 crores
  • Improvement in Margins
Potential triggers (individual or collective) for a downward rating action:
  • Decline in operating performance with EBITDA margins falling below 6.25%
  • Significant increase in debt levels impacting on the financial risk profile
  • Any further elongation in working capital management
Liquidity Position
Adequate

The liquidity of the company stood adequate marked by net cash accruals (NCA) of Rs. 8.55 crores as against long term debt repayment of Rs. 0.15 crores in FY25. NCA is estimated to be in the range of 8-8.50 crores against the debt repayment of Rs.0.89 crores for FY 26(Estd). Further, PIPL’s NCA is expected to be in the range of Rs.10-11 crores for FY 27 and Fy 28 against debt obligation of Rs.1.5-2 crores for the same period. The current ratio stood healthy at 1.69 times in FY25. Fund based Bank limit utilization (BLU) stood at 45% (based on the closing balance) and 69% (based on the maximum utilization) for six months ending Mar’26. Further, average non fund-based BLU stood at 70-80%. Acuite believes liquidity will be adequate in the medium term supported by steady accruals and absence of major debt funded capex plan.

 
Outlook: Stable
­
 
Other Factors affecting Rating
­None
 

Particulars Unit FY 25 (Actual) FY 24 (Actual)
Operating Income Rs. Cr. 159.61 166.26
PAT Rs. Cr. 5.73 8.85
PAT Margin (%) 3.59 5.32
Total Debt/Tangible Net Worth Times 0.11 0.15
PBDIT/Interest Times 6.62 7.91
Status of non-cooperation with previous CRA (if applicable)
­Not Applicable
 
Any other information
­None
 
Applicable Criteria
• Default Recognition :- https://www.acuite.in/view-rating-criteria-52.htm
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm
• Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm
Note on complexity levels of the rated instrument

Date Name of Instruments/Facilities Term Amount (Rs. Cr) Rating/Outlook
03 Mar 2025 Bank Guarantee (BLR) Short Term 12.00 ACUITE A3+ (Reaffirmed)
Term Loan Long Term 6.30 ACUITE BBB | Stable (Assigned)
Cash Credit Long Term 12.00 ACUITE BBB | Stable (Reaffirmed)
Term Loan Long Term 0.10 ACUITE BBB | Stable (Reaffirmed)
04 Dec 2023 Bank Guarantee (BLR) Short Term 12.00 ACUITE A3+ (Reaffirmed)
Proposed Long Term Bank Facility Long Term 0.10 ACUITE BBB | Stable (Reaffirmed)
Cash Credit Long Term 12.00 ACUITE BBB | Stable (Reaffirmed)
­

Lender’s Name ISIN Facilities Listing Status Regulated By Date Of Issuance Coupon Rate Maturity Date Quantum
(Rs. Cr.)
Complexity Level Rating
ICICI BANK LIMITED Not avl. / Not appl. Bank Guarantee (BLR) Unlisted RBI Not avl. / Not appl. Not avl. / Not appl. Not avl. / Not appl. 15.00 Simple ACUITE A3+ | Reaffirmed
ICICI BANK LIMITED Not avl. / Not appl. Cash Credit Unlisted RBI Not avl. / Not appl. Not avl. / Not appl. Not avl. / Not appl. 12.00 Simple ACUITE BBB | Stable | Reaffirmed
Not Applicable Not avl. / Not appl. Proposed Long Term Bank Facility Unlisted RBI Not avl. / Not appl. Not avl. / Not appl. Not avl. / Not appl. 1.30 Simple ACUITE BBB | Stable | Reaffirmed
ICICI BANK LIMITED Not avl. / Not appl. Term Loan Unlisted RBI 28 Mar 2024 Not avl. / Not appl. 30 Jun 2029 2.10 Simple ACUITE BBB | Stable | Reaffirmed
Note:- For activities or ratings of instruments falling under the purview of Financial Sector Regulators other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available.

Contacts

List of instruments and names of regulators of the instruments

© Acuité Ratings & Research Limited. All Rights Reserved.www.acuite.in